MGNX - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon.

We will begin the MacroGenics 2024 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions] At this point, I will turn the call over to Jim Karrels, Senior Vice President and Chief Financial Officer of MacroGenics.

James Karrels

Thank you, operator. Good afternoon, and welcome to MacroGenics' conference call to discuss our third quarter 2024 financial and operational results.

not a chance outlining press has results, review today's who issued we release anyone had to the these announcements. For this afternoon our is at release available the tab This under macrogenics.com. on Investors website

website, expectations, X discussion listen to to purposes future alert those would with the and of as for Actual statements call Private on be Act the in section You may Factors will discussed filed indicated the the annual, that about constitute results where beginning safe Litigation call XXXX. forward-looking including company's this will approximately also it the days like today's these a harbor the and include after Risk result prospects via those provision of current statements listeners our conference statements plans webcast that from reports by our Securities hours for XX SEC. completed. I archived of is under of may various quarterly materially differ factors, Reform forward-looking important

addition, representing views should upon forward-looking relied as of be not of today as and In represent views subsequent only date. statements any as our our any

President turn obligation if call the the While to some do in forward-looking Chief disclaim the Dr. by update applicable Officer future, and required Koenig, extent our Executive I'd even to any to we over now statements we point so, like views change, specifically to of at MacroGenics. these elect may except Scott And law. to

Scott Koenig

call do review afternoon. to everyone updates I will so, our our webcast I key today. to before Thank on turn me who financial you, first Jim, and Jim. this programs will I'd participating results. the let via call welcome back conference like clinical provide But

James Karrels

financial MacroGenics afternoon, the financial position. which This our highlights quarter ended Scott. for September XX, XXXX, you, results Thank reported

XX, Incyte our August the ended revenue XXXX. the in September compared was million retifanlimab. quarter release of $XX.X for million related XX, million total revenue September to in primarily was MacroGenics' in total this due to quarter received $XXX.X ended described $XXX afternoon, from The XXXX increase As for to milestones

Our to was for to the research $XX.X million $XX.X pipeline due research XX, increase costs and of the The to quarter duo ADC and XXXX for compared XX, development trial. quarter increased the company's and development ended ended XXXX. expenses primarily September TAMARACK clinical September were million the preclinical vobra related

for The professional stock-based XX, and were September for million general XXXX fees. the selling, and XX, Our September primarily $XX.X million quarter compensation administrative increase expense the increased to ended XXXX. expenses compared to due ended was quarter $XX.X

ended September included the income Our million was was $XX compared XXXX. the net disclosed net of payment September Net the endpoint the million quarter which from for XX, the for in $XX.X for a $XXX study, milestones XX, the quarter included XXXX previously of Sanofi income. ended milestone million from Incyte. September quarter XX, in a in achievement income XXXX TZIELD other ended clinical a related recorded primary to aforementioned income quarter for million ended to September income Net XX, $XX.X XXXX

million to commercialization MARGENZA million upfront our cash, XXXX XX, and of plan pay $XXX.X equivalents not was the cash the XXXX the XX, fee as the did million balance or September current securities include December transaction balance anticipated amendment September XXXX. $XXX.X compared Our $XX marketable The we XX, of of closing from million as of $X to payment partner.

payment into and our anticipated $XXX.X of the partners prior fee Consistent transaction, balance to cash less from terms cash partner, $XX anticipate our cash of as XX, should pay XXXX, projected of we and future million million securities in $X related we equivalents runway in an to marketable amendment anticipated cash, September TerSera guidance, addition commercialization payments runway. our from expect plus our XXXX. provide Finally, MARGENZA million the with a that upfront to current

ongoing preclinical and call to to funding I'll related expected And Phase II expenditures turn ongoing TAMARACK clinical and studies. Our LORIKEET back reflect as now Scott. studies requirements the anticipated the our as other well

Scott Koenig

Jim. Thank you,

to We proprietary of our great and our has of through walk candidates promise, you will believe key continue pipeline product programs. each I

designed or advantage is involved across BX-HX. multiple of payload this duocarmazine, Vobramitamab vobra solid deliver antigen's of of molecules BX duo a broad our types. tumors ADC duocarmycin in member to regulation. designed DNA-alkylating Vobra to the expressing is family duo, cytotoxic to is take a tumor expression immune BX-HX

an We continue ideal of to attributes the target. cancer BX-HX believe has

being is androgen II have chemotherapy. received X who other study regimen, no prior but to up previously patients targeted The containing agents TAMARACK conducted and in an mCRPC Phase access receptor taxane

study survival, or trial, rPFS. and are disease The dosed no for being in While events, to progression-free the endpoint continue be adverse survival. primary participants monitored participants longer is study's progression radiographic

the ESMO to XX the at immature. only they rPFS that XXXX September were interim additional as Given believe cutoff, had as presented change PSF of XX.X% Congress these X, accrue. estimates events data accrued the likely And are were because events medium July we results or immature, in

We hand expect no to have mature early XXXX. later median than rPFS in

well in future the of the competitive for potential vobra mCRPC, landscape factors, mCRPC, across a our duo will several for development allocation be on as including final portfolio, TAMARACK alternatives and as efficacy treatment vobra our partnering well review clinical safety Assessment in based we of as combination Until I/II efforts resource data Phase opportunities tumor study alternative development of dose complete mCRPC, assessment in the monotherapy development our lorigerlimab. the plus as paused types of we vobra duo duo. other for have opportunity

X Recall other that have clinical BX-HX. target molecules that we

inhibitor incorporating linker MGCXXX, which novel licensed based ADC SYNtecan E, we X is from Synaffix. investigational an topoisomerase payload, a The first,

enoblituzumab, Our second the molecule investigational directed is monoclonal antibody. BX-HX additional Fc-optimized

distinct with More vobra of another targeting duo. exatecan, targeting and that readily with I or MGCXXX incorporates escalation we early hydrospace based same dose tumor molecule MGCXXX believe alternate action utility. the variable study initiated a We specifically, their pathway in of and BX-HX. safety be for potentially We approach to to vobra the combines [ enhance the targeting complementary of regardless technology. different combination a this a mechanisms linker solid view a efficacy on We domain agents BX-HX BX-HX MGCXXX year ] as stages payload X and camper potentially cancers, vobra mechanism the beacon potential clinical duo MGCXXX different that or in remain with having potent tumors. address advanced for validated duo of is MGCXXX used payload. of with in confident Synaffix's the profiles, in contained clinically may and action Phase or patients of the The sequence

are investigator-sponsored, an in II cancer. Phase academic of Regarding collaborators the men enrolling study up enoblituzumab, XXX study HEAT prostate our to with randomized molecule this

bispecific tumor-infiltrating x TILs, abundant CTLA-X are our have lorigerlimab We such lymphocytes, tumor tetravalent preferential Next, which I'll you update cells, to DART blockade most on in dual or designed expressing on as PD-X molecule. microenvironment. PD-X lorigerlimab, the CTLA-X

We alone a in second-line are randomized lorigerlimab, versus and in chemotherapy combination patients. trial docetaxel enrolling CRPC naive LORIKEET the study, docetaxel clinical with Phase II of

on late or study total The anticipate year of the study study planned date. current a treated enrolled be XXX design endpoint XXXX XXX X:X A study and clinical We a primary half the study in to first of early participants to of providing study XXXX. more this in randomized than with of includes completing enrollment data the are update patients the rPFS.

incorporates and molecule CDX minimize bispecific MGDXXX release maintaining is activity a anti-tumor component designed our by next-generation CDX half-life. DART CDXXX dosing intermittent that syndrome cytokine through to while a cytolytic permitting longer

Recall positive Gilead relapsed that with the CDXXX dose during Phase study. of option is the ongoing MGDXXX at I or decision leukemia escalation study malignancies, patients hematologic in Phase to Our monodysplastic I myeloid MGDXXX including predefined syndromes. license acute and refractory points has

payload making an a X and progression target Synaffix's member cancer an FDA. family ADAMX targeting the an novel overexpressed attractive topoisomerase and We X ADC transmembrane the is for of treatment. linker it application proteins second cancers, genesis U.S. drug multifunctional our of and tumor to in investigational is antibody. based submitted is in cancer recently play new MGCXXX for that Type Adams MGCXXX multiple incorporating inhibitor ADAMX a role

for future submission. you about molecules potential to look forward additional calls. exploring IND additional are these we future I MGCXXX, more on molecules Beyond telling

sold us LLC, announced to an aggregate to few $XX company, we of million is MARGENZA, $XX fourth at of quarter closing, to and agreement payments we may end, is a expected The global up to receive rights sales as expected of subject additional which customary Therapeutics an transaction marketed quarter to privately in to million. TerSera milestone pursuant ago. the biopharmaceutical is closing conditions. after XXXX, close weeks held TerSera a Finally, pay margetuximab, to

TerSera We and going current during will to of substance fee on amendment pay forward. fourth behalf MARGENZA drug manufacture expect an million commercialization of XXXX, quarter partner to the $X our

on milestones assets researching in enabling for transaction, from to financial further Thank as our of us as well our our The all joining of product sharpen while advancing developing received pending recently wave key strengthen stage the clinical million $XXX today. focus early you next priorities candidates. stage the our position, Incyte, and margetuximab

transformed down a that Together, years pipeline company treatments. of building MARGENZA, we integrated proud with CEO early dedicated and approval XX we've particularly personally be President TZIELD will stepping robust As After advancement we've as to patients. achieved, ZYNYZ of treatments, our I'm FDA you what know, fully biotech truly to year. like a last into professionally. helping announced antibody-based nearly ideas it's and week therapeutics me immensely next and the and I of milestone MacroGenics, for

for comes This supporting period foundation. thoughtful transition. during development has the search a am a transition time diverse committed with at initiated solid and a promising to portfolio to ensure The seamless strongly a and Board MacroGenics and is positioned I financial a successor, my when company this

MacroGenics' ahead, future. Looking in confident I am

shareholders advancing our now Operator? and support I'm to the for and adviser want dedication. all my continuing alike. to partners our MacroGenics accomplish its be as creating an will team, in Our excited chapter. shareholders I next Board, that would questions. and pipeline, patients see to open and near-term look partnerships remain forward goals our unchanged: to call MacroGenics and value We I expanding for thank for happy the their our shareholder,

Operator

question line Instructions] Cowen. coming the from with [Operator you. of Bancroft Thank TD Tara Now first

Unknown Analyst

on is Tara. This Nick for

X going duo? not into data potential the make to Just but dose any you next excision will year this the about And your specifically me, to from vobra factoring what for have you the do for at for see on updated need thoughts decision parameters understand multiple or forward point? do a I this. But be

Scott Koenig

Nick. you Thank very much,

we close the we to final are data. getting said, As

observation dosing, of As the than noted, July. be longer no in The X will post followed continued the last more we've months. these we patients occurred patients which

have we final looking drug, in will at looking the our profile As the It's of look early rPFS, steps context this pointed which of landscape determine of to other looking the number at things assessing at give at forward. the obviously, point to parameters parameters competitive out, the in this I at, the safety and portfolio. too just the specific next

be coming be to patient, insights able some So months. provide in we the should and

Unknown Analyst

you Thank much. very

Operator

Our next the of question coming Chang from Leerink with Partners. Jonathan line

Jonathan Chang

course, And best Scott. of wishes to

the can Can for from how color should how could program? First for question, around the initial time provide progressing? next data MGCXXX, when transition? dose point, Phase thinking second process on second CEO? program. search clinical about on escalation lines And see that is question, ADC that investors And the the And I you any discuss you then your be BX-HX we

Scott Koenig

It's always you pleasure with First, working a much. you. very thank Jonathan, been

process that until been have adopted of the as and while new the stay of terms be with -- and occurred search last is I with will that We're to is to search Board the CEO initiate firm, selected expectations, selected. started. week, is strategy is the said, subgroup programs move the process I committee the a announcement going The as forward on. working there just outside going we an In the getting to has a continue is the that process,

middle on anyone would is 'XX. anticipated. study a these will now. that expectation selected hand the we there into few comes one take able -- regard data We're out dose might study right the 'XX should on is quite of off months. The new the complete things to We're stay be XXX ranges of With person responsiveness. study, board. is the Obviously, -- when anticipate in It's be escalation. in in going this we to so until we're to here CEO that smooth the report beginning would well. and The getting begin I a

Operator

next of Nochomovitz Our the Yigal question coming line Citi. from with

Unknown Analyst

pausing stop when Reena versus ] could on seen And dosing earlier of what help is This patients wanted the if triggered I to now there [ any combo [ ] any monotherapy? Yigal. for [ combo decision the ] in were the vobra to [ you was lorigerlimab kind [ ], just more in ] service Were Or to seen details many decision with [ provide the might ask ] TAMARACK? dosed? there? color on patients we've how vobra on the you color the have what just additional any

Scott Koenig

question. Thank you the very much for

know, As the were doses we were in individual that you the point proceeded combination. in study combo with vobra the the we we the very comfortable and had lorigerlimab populations examining to with were achieved with where

get coming as we that, couple additional we had forward. We pointed vobra the to in tested that possibility of we assessment therefore, dose before that the are rather moving And the would for in combination, appropriate However, final next then the than wanted explore if with at exploring up forward of combinations vobra we final out, that TAMARACK appropriate. and of is fine-tune doses at going to would we looking studies already months. in data expansions the look continue

judgment a continue the combination it's we studies. if want So forward to dose that we going ultimately best have

Unknown Analyst

makes sense. That Okay.

Operator

Markets. Darout our line with BMO Capital And of coming question from next the Etzer

Etzer Darout

Just MGCXXX. X question me on for

in you've given evaluated vobra duo the wonder, preclinically clinic. and Just now

gotten preclinical assessment a MGCXXX. of You've

profile If vobra differentiated safety? that in and any you're the could from from on of seeing profile safety sort notable be how a ADCs differences those for X perspective

Scott Koenig

agent being inhibitor, Etzer. a Thanks, safety expect would being obviously, One the a X will with XXX see that, distinct vobra DNA-alkylating profiles. one Topo and

but escalation be TAMARACK get side-by-side spell early achieved the study specifics with lowering point. just you middle a this to the We give safety, it's point, There being at to there. on a XXX, two. too I obviously final much want out safety. can't doses comparison the the this of differences of we the will distinct in at said, with only in But dose I've As the

Operator

Thank you.

ISI. with next question Our Evercore Jon Miller coming from

Jonathan Miller

with And I'd dosed and And is forward respect vobra duo is it's for you've other could for time lori we lori to term you patients have rate? my have? here, coming much these whether there many the the data? I'll about data Scott, you you work any lori around echo all pausing. combinations a see you're for heard do any that years. before, How love vobra as ask combo great to also chance How near same or how from in the Maybe at that that And prostate? LORIKEET perspective, do out the maybe ADCs landscape in view with going from you with or there?

Scott Koenig

of a Jon. answer actual you much, is appreciate comments. to to the really so With with of Thanks did I colleagues Yes. I top the number But digits. many personal can't and to specific the we the your patients, working It well. -- head. the you regard and be double pleasure my is off in as numbers

types, with assessment any looking plus various particular quite of at different tumor type were X because patients terms we tumor enrolling at X was was But In small. multiple representation the a combinations. of course, this of doses,

will the haven't with the you results the presenting we point, said I docetaxel. continue likely forward. With the combination going the in doing combination have early more TAMARACK, form alterations the 'XX. the And year opportunity end the need this very enroll whether we make study regard final of with as LORIKEET earlier, study we completely there that I studies are at decisions, of that, we noted we data in the lorigerlimab, know, by some of or is earlier, we with to further as to as if want dosing assessed vobra of So assess

LORIKEET settings, again, assess other on of combining have we until with clinical that. cancer, looking have prostate data data And are to but opportunities in only final early on at agents, the the other 'XX too and lorigerlimab it's, not So we'll we that study. on

James Karrels

Let just that, it to me to listeners. in completely just clear add wasn't case

We in had not with later move studied So we the dose this do expansion that would -- dose year. escalation. plus Obviously, only we've combination, vobra lori, regard that. to thought into did we that

never our actually study the So comes escalation expansion dose commenced. and data all was of dose from

Scott Koenig

a out, pointing was Jim looking it at again, plus as design X Yes, that. was X in

Operator

our line Partners. Guggenheim Kelsey And from of Goodwin coming the question next with

Unknown Analyst

[indiscernible] on for [ Kelsey ].

the Just next and coming tell first [ the ] trial half the of year. about update LORIKEET me in that's

what there of terms would In be the benchmark and considered?

Scott Koenig

with Thanks study. the regard LORIKEET very to much

a soft looking want You were chemo-naive a I little sound was. population. what on just understood everybody the the sure here. at question to we're make here Clearly,

if X.X to we to the care significant and rPFS obviously, docetaxel Clearly, look last at you it's in of if then see standard the in both ultimately, alone, rPFS have increase, seen OS, X approximately know, look you X a was like benefit. months of where As at studies would docetaxel of actual you a number. tested, the benefit

point, be are for position certainly this double-digit at in -- in certainly a would months be a declare to We a not will improvement. of but rPFS, in

Operator

coming our Silvan from And the next Tuerkcan with JMP. Citizens line question of

Silvan Tuerkcan

I And It Scott, to working was work great on with for have you. question with us. MGDXXX. a thank you

out Gilead You've could may this ongoing next trial, mentioned and not or may opt-in those and -- points option the year various points is some any year. not? are of it year But find has or throughout next get for we you data that at next

Scott Koenig

well. thank to again, With very your the to comments. personal much, It's it's you -- regard proceeding study,

already, you dose active one that escalation. FDA dose with escalate and many, are killing here. to we know, through slow As we've been T-cell cohorts And an molecules, requires continuing redirected is the position many

They I wait data. of in. And end to the It this the moving when make will regard at have the to Phase completed. the might Gilead forward. decision can determine I study So until point, is I can't, the with opting be ability determine nor when

We and share we this study with have So point, collaboration. will expect that continue. we data good the them, at a the though, very

Operator

Thank question our you. Mamtani Mayank coming B. And Securities. with from next Riley

Mayank Mamtani

Scott long question. And One of congrats picture a list missed. to for you'll big be accomplishments,

focus -- on as relatedly, an bit have of both assess cancer And and prostate a us year, for PRB late-stage to maybe if next specific get ] you're comparability organization getting could direct strategy in your guidance, shift program MacroGenics? Could chapter both to development? this kind precise CRPC we when You've to all, [ as to And the also cancer. and you of tended of then XX and terms see I see a to we give data at a if for able to next programs a follow-up. lung

Scott Koenig

very years opportunities comments certainly personal for you prostate patients. Thank the range cancer, molecules much, a to that there which the again, was treatments, late-stage we of number ago appropriate are on particularly development there, prostate a to for tumors. a We strongly pursuing. a is developing well. treatments for solid as multiple of of because need that regard cancer the on wide embarked we're lack focused With the obviously There and of led of the and company

well you over expect And As continue will with the we as programs I've of BX-HX that. we that the XXXX. know, And course discussed lorigerlimab. results as the

regard to With XXX, about as we've duo. talked vobra

with escalation expansions. I escalation going the study, open XXX we tumors. is BX-HX in we're a built range to plan do into drug positive the of lot determine forward ability looking The the responses is the to dose dose have at to a So types. tumor many have The use wide in that of to this patients Phase XXX, different of

what pursue with it's data middle as only as I But to a dose the further. responses early for this prostate regard we're types tumor we well. indicated, point, have as and to again, we too types might so in should at specific escalation, other that XXX, tumor of we result, expect in in determine And

Mayank Mamtani

say, [ ] regarding Great. which expectation as learnings. taxane. your of report tumor, generally wondering case X the of VDs to BX-HX remains And is expression could TAMARACK you expression intend maintained TAMARACK data? could going specific The then comparable the PSMA. post be And this be because it's the preimposed I and forward that different was question than final efficacy if

Scott Koenig

Yes.

the at, both the look So chemo-naive obviously, continuing we and TAMARACK the data. settings for to are post-taxane

indicated, at frame very of As chemo-experienced as chemo-naive both we the as are having months, ESMO well we landmark showed the getting time we're responses population. X at and the good in

as to this we still providing down But of All the point, open out to when it's the this final degree the we there until the the both we well well treatment, at pursue for that So right things pointed earlier, as we of have final if assessed a paradigm have population. now, I data. assess further. lot new haven't will safety activity, as data, in potentially as chemo-experienced are profile. Again, we rPFS, the the chemo-naive as comes a

Mayank Mamtani

to Are relative characteristics, results LORIKEET that done maybe to that longer? also year? exposure, SMA And Or patient prior trial status to will the here, Understood. you treatment OS And Scott. for if trials the would how could comment enrollment completion ] compare could mCRPC lastly, been getting able have just [ in you baseline docetaxel the take next previously? clarify available be on the

Scott Koenig

regard LORIKEET, With was chemo-naive of the these similar what for the that quite the population to say was I to patients TAMARACK. in enrolled characteristics would patients the for

had an obviously progression agent. they targeting receptor androgen So on

be would who are own of we normally is there standard to will regimen or characteristic patients patients And for the historical so this compared controlled have agent data. see that think have as what this get seen we alone to with on a that XX fact population are trial, our that alone that that is a does will so the very docetaxel. The what we in as docetaxel data treated

feeling confident will set as will pretty compared data have studies. that valuable nicely I'm be that So to historical a we

in think 'XX, early responses, year this little OS, to obviously, in present, a to very able as in But the or rPFS as that survival, regard good too to be study very shape maybe the will in given end 'XX. with but completely Now out by said, we be we'll will that, early. overall it enrolled think early I 'XX, PSA be reductions of report well as be to I

Operator

line question Lawson And with Barclays. of Peter the coming our from next

Peter Lawson

BX-HX that data? Great. see do BX-HX forward? guess we assets, your understand think as what that, your first to how molecule, far about and generation of that do kind to we I see that second-generation of is in I kind if I want your And when behind moves you guess how the guess, initial

Scott Koenig

comment, you very know, number you of as molecules are a there To are Peter. other moving that forward. much, Thank

that Topo number For conjugation presented has fact that forms. we here DARX types, tumor in broad Synaffix of for that ] opportunity X that scientific the inhibitors, the that's the particular a see designed of we other that been data of types. to in to perform could And tumor to and competing the quite XXX in profiles a obviously, expression number of virtues the of we been feel was the way [ with different development regard been because has presented as many well. of data compared this molecules the Again, the BX-HX limited may despite in the behind then others site-specific with of having exatecan is be with that different molecule a date

been from that feel other that cancer been cancers, in cases, And lung modest in particularly the there shown so has has data fact we we in available small despite And and study some that competitive to the we cell data 'XX. expect in be quite earlier, dose Phase be as data once we said molecule I I finish can with XXX the escalation.

based but duo largest prostate again we again, here. in necessary the vobra what prostate early have it's safety and we is the the just dosing whether move achieve into data final set necessary to indication. to have the data a go-forward will to a will molecule, cancer final Clearly, out on for with spell further assess to profile opportunity the With forward as vobra tweaking plan too to well be rPFS regard as duo, the

stay prospects our We're tuned. BX-HX the molecules. very both still of ADC encouraged by So of

Peter Lawson

talk always Scott, over to Great. to it's you pleasure been the year. a

those So having all conversations.

Scott Koenig

Thank you same here. And much. very

Operator

with Our Willey Stifel. line you. question coming the of Thank from Stephen [Operator Instructions] next

Stephen Willey

quick of to to over say enjoyed best luck First, I I all just wanted second, you, And question MGCXXX. Scott. the just certainly the then on a have years. interactions

dose specific program. tumor going that a curious the ran it few them, for it tumor or types? that interested know program not I Phase to I Just types as that escalation If think be outlined ImmunoGen Phase is was whether remember were development I prespecifying different I correctly, you I in with had as stopped about. tumor curious if list different to partner payloads? the inherent to wondering tumors you've just given different be as obviously information obviously. tumors thinking that has that what could sensitivity would out, of if just types to just you're changed, But some give of you payload there's And a an

Scott Koenig

Thanks, And limit you with Steve. always to we over yes, working answer tumor The again, going real pleasure, Yes. is types the a specific are years. the going forward.

in data a as in As you data, types. tumor number IHC our shown overexpression preclinical of well as know, we've particular, this -- own based on

obviously tumors the that type least at and as among you tumor and would well. pancreatic lung expect X So cancer could be cancer another

the able dose as drug. to So us best as the of we we activity that obviously safety signals well as feel that escalate be sense give profile will to the see

know, of because never you is observed. the molecule challenges As toxicity on the high targeted dose that to able of the the we were that ImmunoGen was X achieve

Operator

at And back remarks. I closing over the this questions time, for further queue. Q&A any now Koenig Dr. turn in see to no will I the call

Scott Koenig

go our again, for you you, and programs And on activity done other call. personally. earnings vote look exciting your forward thank and on remarks it we everyone, obviously, already. if Well, haven't company-related our to updates providing out next And kind

James Karrels

everyone. night, Good

Operator

and that for Ladies gentlemen, does your conclude participation. our today. for you Thank conference

disconnect. now may You

MacroGenics (MGNX) 5 Nov 242024 Q3 Earnings call transcript